Fresenius Medical Care AG (FMS)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
- Symbol
- FMS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $6.86B
- 52 week range
- 20.02 - 27.64
Valuation
- Share price
- $22.41 (close of 2026-09-23)
- P/E (TTM)
- 8.00x
- Price to book
- 0.60x
- Price to free cash flow
- 6.18x
- Enterprise value
- $13.92B
- Book value per share
- $37.41
Price performance
| Period | Change |
|---|
| 1 day | +0.86% |
| 5 days | -2.40% |
| 1 month | -4.35% |
| 3 months | -5.44% |
| 6 months | +2.33% |
| Year to date | -5.92% |
| 1 year | -12.77% |
| 3 years | -0.79% |
| 5 years | -37.37% |
| 10 years | -49.46% |
| All time | +112.22% |
Profitability and growth
- Return on equity
- 10.85%
- Return on invested capital
- 10.55%
- Return on assets
- 4.62%
- Return on capital employed
- 12.05%
- Net income growth
- 20.77%
- Free cash flow growth
- 10.21%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 16.17%
- Current ratio
- 1.45x
- Net debt to EBITDA
- 2.07x
Latest reported year
- Period end
- 2016-12-31
- Fiscal year
- 2016
- EBITDA
- $3.41B
- Net income
- $1.24B
- Earnings per share
- $4.07
- Research and development
- $162.36M
- Interest expense
- $452.18M
- Shares outstanding
- 305.75B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2016-12-31 | - | - | $1.24B | $4.07 |
| 2015-12-31 | - | - | $1.03B | $3.38 |
| 2014-12-31 | $5.27B | $5.00B | $1.05B | $3.46 |
| 2013-12-31 | $4.97B | $4.74B | $1.11B | $3.65 |
| 2012-12-31 | - | - | $1.19B | $3.89 |
| 2011-12-31 | - | - | $1.07B | $3.54 |
| 2010-12-31 | - | - | $978.52M | $1.63 |
| 2009-12-31 | - | - | $891.14M | $1.50 |
| 2008-12-31 | - | - | $817.61M | $1.38 |
| 2007-12-31 | - | - | $717.13M | $1.22 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2016-12-31 | - | - | 10.85% | 10.55% |
| 2015-12-31 | - | - | 9.81% | 9.51% |
| 2014-12-31 | 94.88% | 19.85% | 10.42% | 9.01% |
| 2013-12-31 | 95.33% | 22.33% | 11.70% | 9.96% |
| 2012-12-31 | - | - | 12.89% | 9.82% |
| 2011-12-31 | - | - | 13.29% | 11.14% |
| 2010-12-31 | - | - | 13.01% | 11.22% |
| 2009-12-31 | - | - | 13.11% | 11.24% |
| 2008-12-31 | - | - | 13.72% | 18.63% |
| 2007-12-31 | - | - | 12.88% | 21.16% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2016-12-31 | $747.23M | $7.20B |
| 2015-12-31 | $549.50M | $7.85B |
| 2014-12-31 | $633.86M | $9.01B |
| 2013-12-31 | $682.78M | $7.75B |
| 2012-12-31 | $688.04M | $7.79B |
| 2011-12-31 | $457.29M | $5.49B |
| 2010-12-31 | $522.87M | $4.31B |
| 2009-12-31 | $301.23M | $4.43B |
| 2008-12-31 | $221.58M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2016-12-31 | $1.11B | $25.69M |
| 2015-12-31 | $1.01B | $6.58M |
| 2014-12-31 | $929.76M | $6.31M |
| 2013-12-31 | $1.29B | $13.59M |
| 2012-12-31 | $1.36B | $2.31M |
| 2011-12-31 | $848.63M | $2.60M |
| 2010-12-31 | $844.50M | $2.60M |
| 2009-12-31 | $765.01M | $1.54M |
| 2008-12-31 | $329.04M | $2.19M |
| 2007-12-31 | $626.85M | - |
Dividend history
- Most recent payment
- 2026-05-22
- Paid in the last twelve months
- $0.87
| Payment date | Dividend per share |
|---|
| 2026-05-22 | $0.87 |
| 2025-05-23 | $0.81 |
| 2024-05-17 | $0.63 |
| 2023-05-17 | $0.62 |
| 2022-05-13 | $0.71 |
| 2021-05-24 | $0.83 |
| 2020-08-28 | $0.71 |
| 2019-05-17 | $0.66 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-03 | Jun/2026 | - |
| 2026-05-05 | - | - |
| 2026-02-24 | - | - |
| 2025-11-04 | - | - |
| 2025-08-05 | - | - |
| 2025-05-06 | - | - |
| 2025-02-25 | - | - |
| 2024-11-05 | - | - |
Filings and sources
- Company website
- freseniusmedicalcare.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades